E
Aprea Therapeutics, Inc. APRE
$1.43 -$0.02-1.38% NASDAQ
Recommendation
Prev Close
$1.45
Volume
36,439
Avg Vol (90D)
73,431
Market Cap
$8.45M
Dividend & Yield
--
52-Week Range
$1.31 - $5.00
P/E (TTM)
--
EPS (TTM)
-$2.31
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Aprea Therapeutics (NASDAQ:APRE) Trading 2.1% Higher - Here's What Happened
10/30/2025 - Ticker Report
Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors
10/27/2025 - TipRanks Financial Blog
Aprea Therapeutics Advances with Phase 1 Study of APR-1051 in Solid Tumors
10/27/2025 - TipRanks Financial Blog
Aprea Therapeutics (APRE) Provides Update on Phase 1 Trial Success
10/24/2025 - GuruFocus
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of ...
10/24/2025 - GuruFocus
Aprea Therapeutics Reports Promising Trial Results for APR-1051
10/24/2025 - TipRanks Financial Blog
Aprea Therapeutics provides update from ACESOT-1051 t rial
10/24/2025 - The Fly
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
10/24/2025 - Globe Newswire
Aprea Therapeutics (APRE) Advances ATRN-119 with Phase 2 Dose Decision
10/15/2025 - GuruFocus
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering ...
10/15/2025 - GuruFocus
Aprea Therapeutics establishes RP2D for ATRN-119
10/15/2025 - The Fly
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
10/15/2025 - Globe Newswire
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on ...
10/14/2025 - GuruFocus
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
10/14/2025 - Globe Newswire
Aprea Therapeutics Highlights Progress in Clinical Trials
9/8/2025 - TipRanks Financial Blog
Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference APRE Stock News
8/28/2025 - GuruFocus
Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference
8/28/2025 - GuruFocus
Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference
8/28/2025 - Globe Newswire
Aprea Therapeutics Second Quarter 2025 Earnings: US$0.53 loss per share (vs US$0.58 loss in 2Q 2024)
8/14/2025 - Simply Wall St
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update
8/12/2025 - GuruFocus
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update ...
8/12/2025 - GuruFocus
Aprea Therapeutics sees cash runway into 2Q26
8/12/2025 - The Fly
Aprea Therapeutics reports Q2 EPS (53c) vs. (58c) last year
8/12/2025 - The Fly
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update
8/12/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
$841.00K
EBITDA (TTM)
-$14.77M
EBIT (TTM)
-$14.80M
Net Income (TTM)
-$13.85M
Balance Sheet
Total Assets (Q)
$17.31M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$3.17M
Book Value Per Share (Q)
$2.33
Cash Flow
Cash from Operations (TTM)
-$12.74M
Cash from Investing (TTM)
$0.00
Cash from Financing (TTM)
$573.90K
Net Change in Cash (TTM)
-$12.16M
Filings
Filing Date
Tuesday, August 12, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Loading...
Beta
2.24
7-Day Total Return
-6.54%
30-Day Total Return
-0.69%
60-Day Total Return
-13.33%
90-Day Total Return
-20.56%
Year to Date Total Return
-59.94%
1-Year Total Return
-63.43%
2-Year Total Return
-57.44%
3-Year Total Return
-89.33%
5-Year Total Return
--
52-week Low
Oct 28, 2025 - $1.31
52-week High
Jan 03, 2025 - $5.00
Valuation
Market Cap
$8.45M - Nano Cap
Enterprise Value
-$7.36M
Price/Sales (TTM)
10.49
Price/Book (Q)
0.62
Dividends and Shares
Shares Outstanding
6.08
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
aprea.com
Phone Number
215 948 4119
Address
3805 Old Easton Road
Doylestown, PA 18902
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage... more
NASDAQ 10/31/2025 1:48PM Eastern Quotes delayed